ZOL.L Regulatory News (ZOL)

21 Feb 2007 13:39

Crosby Capital Partners Inc21 February 2007 RNS REACH CROSBY CAPITAL PARTNERS INC. ("CROSBY") CROSBY'S DRAGON FUND TAKES UP PLACEMENT IN FERMISCAN 21 February 2007 Crosby announces that the Dragon Fund Inc., managed by Crosby Asset Management,has subscribed for a placement of 8.5 million new ordinary shares in FermiscanHoldings Limited ("Fermiscan", Stock Code: FER AU) at A$1.50 per share for totalconsideration of A$12,750,000 (£5,135,317). Techpacific Capital Limited, whichowns 81.04% of Crosby, is beneficial owner of 5.8 million of these sharesthrough its shareholding in the Dragon Fund Inc.. The total share placement byFermiscan raised A$22.5 million ("Fermiscan Share Placement") and the new shareswill rank equally with its existing shares and are expected to trade on the ASXwith effect from Monday 12 March 2007. The full text of Fermiscan's announcement on the ASX can be found below. Theoriginal is available at the following link: http://www.fermiscan.com.au/Documents/070216ASXSharePlacementAnnouncement.pdf#a160207 Company Announcements Australian Stock Exchange Limited Exchange Centre20 Bridge StreetSydney NSW 2000 16 February 2007 SHARE PLACEMENT OF $22.5 MILLION Fermiscan Holdings Limited advises that it has raised $22.5 million in a shareplacement. The company will issue 15 million fully paid ordinary shares at anissue price of $1.50 to Australian and international institutions and professional and sophisticated investors. The proceeds from the placement will be used to fund; •Anticipated capital expenditure relating to access to dedicated Synchrotron beam lines including the x-ray diffraction equipment necessary to perform the Fermiscan test. •Developing international and domestic markets for the Fermiscan technology. The company plans to market the Fermiscan test globally, and is currently examining selected markets in South East Asia and Japan. •Working capital. The proposed issue of new shares will rank equally with existing shares and isexpected to trade on the ASX effective Monday 12 March 2007. About Fermiscan Holdings Limited Fermiscan is an Australian listed company with a market capitalization of A$275million. Fermiscan is launching an innovative test for the detection of breastcancer using hair. The breakthrough technology that underpins the FermiscanTMTest is the discovery by an Australian scientist that breast cancer changes thestructure of hair, and that this change can be detected using a technique knownas synchrotron X-ray diffraction. The finding has been published ininternational peer reviewed scientific journals, and has been patented inseveral countries. This test, unlike alternatives, is non-invasive and issuitable for all women. Preliminary data indicates that it may also provideearly detection of breast cancer. Early detection of breast cancer has manybenefits to the individual, which range from increased probability of survival,increased treatment options and improved quality of life. The FermiscanTM Testis expected to be commercially available in 2007, after the validation trial hasbeen conducted. Further details can be found on the company's website:www.fermiscan.com.au. About Crosby Capital Partners Crosby Capital Partners Inc. is a leading independent deal-focused Asia-orientedmerchant banking and asset management group. Crosby is quoted on the AIM marketof the London Stock Exchange. Further details can be found on the company'swebsite: www.crosby.com For further information on Crosby please contact: Simon Fry, Chief Executive Officer on +44 20 7590 2800Steve Fletcher, Chief Operating Officer on +44 20 7590 2800 This information is provided by RNS The company news service from the London Stock Exchange